Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Edward Swanson
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, Eric Swanson wrote the following 2 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival. 2017

Williams, Jennifer L / Chan, Carmen K / Toste, Paul A / Elliott, Irmina A / Vasquez, Charles R / Sunjaya, Dharma B / Swanson, Eric A / Koo, Jamie / Hines, O Joe / Reber, Howard A / Dawson, David W / Donahue, Timothy R. ·Department of Surgery, Harbor-UCLA Medical Center, Los Angeles, California2Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles. · Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles. · Department of Pathology, University of Utah, Salt Lake City. · Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California. · Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles. · Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles6Department of Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles. ·JAMA Surg · Pubmed #27732711.

ABSTRACT: Importance: Patients with periampullary adenocarcinomas have widely variable survival. These cancers are traditionally categorized by their anatomic location of origin, namely, the duodenum, ampulla, distal common bile duct (CBD), or head of the pancreas. However, they can be alternatively subdivided histopathologically into intestinal or pancreaticobiliary (PB) types, which may more accurately estimate prognosis. Objectives: To identify factors associated with survival in patients with periampullary adenocarcinomas and to compare survival between those having intestinal-type or PB-type cancers originating from the duodenum, ampulla, or distal CBD with those having pancreatic ductal adenocarcinoma (PDAC). Design, Setting, and Participants: This study was a retrospective analysis of medical records in a prospectively maintained database. Three pathologists separately evaluated histopathologic phenotypes at a university-based tertiary referral center. Study participants were all patients (N = 510) who underwent pancreatoduodenectomy for adenocarcinoma between January 1995 and December 2014. Main Outcome and Measure: Overall survival. Results: This study identified 510 patients (mean [SD] age, 66.1 [10.9] years; 245 female [48%]) who underwent pancreatoduodenectomy for adenocarcinomas: 13 duodenal, 110 ampullary, 43 distal CBD, and 344 PDAC. The median overall survival was 61.2 (interquartile range [IQR], 22.0-111.0), 70.4 (IQR, 26.7-147.7), 40.6 (IQR, 15.2-59.6), and 31.4 (IQR, 17.3-86.3) months for patients with cancers of the duodenum, ampulla, distal CBD, or pancreas, respectively (P = .01), indicating a significant difference between the 4 tumor anatomic locations. Most duodenal (61.5% [8 of 13]) and ampullary (51.8% [57 of 110]) cancers were intestinal type, and most distal CBD tumors were PB type (86.0% [37 of 43]). Those with intestinal-type duodenal, ampullary, or distal CBD adenocarcinomas had longer median overall survival than those with PB type (71.7 vs 33.3 months, P = .02) or PDAC (31.4 months, P = .003). There was no survival difference between PB-type cancers and PDAC (33.3 vs 31.4 months, P = .66). On multivariable analysis, histologic grade (hazard ratio [HR], 1.98; 95% CI, 1.56-2.52; P < .001), histopathologic phenotype (HR, 1.75; 95% CI, 1.16-2.64; P = .008), and nodal status (HR, 1.45; 95% CI, 1.12-1.87; P = .05) were significantly associated with survival, while anatomic location was not. Conclusions and Relevance: Histopathologic phenotype is a better prognosticator of survival in patients with periampullary adenocarcinomas than tumor anatomic location. Those with PB-type duodenal, ampullary, or distal CBD adenocarcinomas have survival similar to those with PDAC.

2 Article Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. 2010

Ito, Hiromichi / Abramson, Michael / Ito, Kaori / Swanson, Edward / Cho, Nancy / Ruan, Daniel T / Swanson, Richard S / Whang, Edward E. ·Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA. ·J Gastrointest Surg · Pubmed #20224984.

ABSTRACT: BACKGROUND: The aims of this study were to evaluate contemporary outcomes associated with the surgical management of pancreatic neuroendocrine tumors (PNETs) and to assess the prognostic value of the World Health Organization (WHO) classification and TNM staging for PNETs. METHODS: The medical records of 73 consecutive patients with PNETs treated at a single institution from January 1992 through September 2006 were reviewed. Survival was analyzed with the Kaplan-Meier method (median follow-up: 43 months). RESULTS: Median patient age was 52 years (range, 19-83 years), and 36 (49%) patients were male. Thirty-three patients had a well-differentiated neuroendocrine tumor (WDT), 26 had a well-differentiated neuroendocrine carcinoma (WDCa), and 14 had a poorly differentiated neuroendocrine carcinoma (PDCa). Fifty (68%) patients underwent potentially curative resection, and the 5-year disease-specific survival (DSS) rate for the entire cohort was 62%. WHO classification and TNM staging system provided good prognostic stratification of patients; 5-year DSS rates were 100% for WDT, 57% for WDCa, 8% for PDCa, respectively, by WHO classification (p < 0.001), and 100% for stage 1, 90% for stage 2, 57% for stage 3, and 8% for stage 4, respectively, by TNM stage (p < 0.001). Among the patients who underwent potentially curative resection, nodal status, distant metastasis, and tumor grade were significant prognostic factors. CONCLUSION: WHO classification and TNM staging are useful for prognostic stratification among patients with PNETs.